Replies to post #379055 on Anavex Life Sciences Corp (AVXL)

[frrol]

The wording change was not necessary, but is nice to see. Yes likely had to do with aligning to prominent previous trials like lecanemab.

Our endpoint selection was good, in line with regulatory expectations and current AD research norms. Will be great to see what our 2b/3 trial shows. 500+ patients, while relatively small on its own, is reliable enough for the volatility of these endpoints over almost 12 months to show some credible signal.

[boi568]

My point is that the original endpoint phrase "change in cognition" is not the same as "improvement in cognition." It was therefore ambiguous. You are reading more specificity into the original phrase than existed.